Dupixent® (dupilumab) Pivotal Trial Meets All Primary and Secondary Endpoints Becoming First Biologic Medicine to Significantly Reduce Signs and Symptoms of Moderate-to-severe Atopic Dermatitis in Children as Young as 6 Months
Our Clinical Pipeline
Our story is unusual, with remarkable consistency of leadership and purpose in our efforts to accelerate the drug discovery and development process.
Through responsible business practices and with the highest standards of integrity,
we rise to any challenge w...Read more